Drug · CHEMBL416
METHOXSALEN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. METHOXSALEN. Drugs and targets, record CHEMBL416. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL416
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 8-methoxsalen, METHOXSALEN COMPONENT OF SM-88, Metoxalen, NSC-45923, Oxypsoralen, Puvalen, Vitpso
- ChEMBL
- Open Targets' highest stage
- Approval, for 4 of its 25 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases25
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 25Source Open Targets
See all 25 diseasesTrials27
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03512756 | A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer | Phase 2/3 | 130 | 2024-11-06 | methoxsalen, sm-88 | Its name | ClinicalTrials.gov |
| NCT01380535 | Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) | Early phase 1 | 60 | 2019-10-29 | methoxsalen | Its name | ClinicalTrials.gov |
| NCT02524847 | Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease | Phase 3 | 29 | 2020-09-11 | methoxsalen | Its name | ClinicalTrials.gov |
| NCT02296346 | Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis | 13 | 2019-08-14 | methoxsalen | Its name | ClinicalTrials.gov | |
| NCT02322190 | Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD | Phase 2 | 5 | 2020-03-12 | methoxsalen | Its name | ClinicalTrials.gov |
| NCT00056056 | Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides | Phase 3 | 93 | methoxsalen | Its name | ClinicalTrials.gov | |
| NCT00221000 | Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis | Phase 2 | 86 | methoxsalen | Its name | ClinicalTrials.gov | |
| NCT03605940 | A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease | Phase 2 | 78 | methoxsalen | Its name | ClinicalTrials.gov | |
| NCT05680558 | Photopheresis in Early-stage Mycosis Fungoides | Phase 2 | 74 | methoxsalen | Its name | ClinicalTrials.gov | |
| NCT00054613 | Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease | Phase 2 | 72 | methoxsalen | Its name | ClinicalTrials.gov |
1 to 10 of 27
See all 27 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ECP Methoxsalen + SoC vs Standard of Care (SoC): deaths from any cause | 4 of 29 | 0 of 31 | 60 | NCT01380535 | Trial comparisons |
| ECP Methoxsalen + SoC vs Standard of Care (SoC): serious adverse events | 8 of 28 | 9 of 28 | 56 | NCT01380535 | Trial comparisons |
| ECP Methoxsalen + SoC vs Standard of Care (SoC): Number of Participants With an Overall Response at Week 28 | 20 of 29 | 14 of 24 | 53 | NCT01380535 | Trial comparisons |
| Corticosteriod Arm vs Extracorporeal Photopheresis: deaths from any cause | 0 of 7 | 1 of 6 | 13 | NCT02296346 | Trial comparisons |
| Corticosteriod Arm vs Extracorporeal Photopheresis: serious adverse events | 0 of 7 | 1 of 6 | 13 | NCT02296346 | Trial comparisons |
Papers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Paced Visual Serial Addition Test | 1 | 1 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL416
GET https://conductscience.org/api/drugs/v1/CHEMBL416/diseases?page=2